A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer

An Open-label Study of the Safety, Tolerability, and Response Rate of Xeloda in Treatment-naïve Patients With Metastatic Colorectal Cancer

This study will evaluate the efficacy, safety, and pharmacoeconomics of oral capecitabine in patients with metastatic colorectal cancer. The anticipated time on study treatment is 3-12 months, and the target sample size is 28 individuals.

Inclusion Criteria:

• Adult patients greater than or equal to (>=) 18 years of age
• Metastatic colorectal cancer

Exclusion Criteria:

• Previous cytotoxic chemotherapy or immunotherapy for advanced or metastatic disease
• Central nervous system and bone metastases
• Moderate or severe renal impairment
• Clinically significant cardiac disease
• Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication
• Malignancy within the last 5 years, except cured basal cell cancer of skin and cured cancer in situ of uterine cervix